Illumina, Inc. (NASDAQ:ILMN) Short Interest Up 5.3% in March

Illumina, Inc. (NASDAQ:ILMNGet Free Report) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 5,210,000 shares, an increase of 5.3% from the February 29th total of 4,950,000 shares. Based on an average daily trading volume, of 1,780,000 shares, the short-interest ratio is presently 2.9 days.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ILMN shares. Stephens reissued an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research note on Wednesday, February 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $258.00 price target on shares of Illumina in a research report on Friday, February 9th. OTR Global reissued a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. TD Cowen downgraded Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price on the stock. in a research report on Thursday, January 4th. Finally, Bank of America downgraded shares of Illumina from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $140.00 to $100.00 in a research note on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $166.95.

View Our Latest Analysis on Illumina

Illumina Stock Down 0.6 %

NASDAQ ILMN opened at $127.74 on Thursday. The stock’s 50 day simple moving average is $138.12 and its 200 day simple moving average is $128.76. Illumina has a one year low of $89.00 and a one year high of $232.88. The firm has a market cap of $20.30 billion, a PE ratio of -17.40 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29.

Illumina (NASDAQ:ILMNGet Free Report) last announced its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period last year, the company posted $0.14 earnings per share. As a group, sell-side analysts forecast that Illumina will post 0.91 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In related news, CEO Jacob Thaysen purchased 7,330 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The stock was acquired at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the acquisition, the chief executive officer now owns 14,861 shares in the company, valued at approximately $2,010,544.69. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is currently owned by insiders.

Institutional Trading of Illumina

Several hedge funds have recently modified their holdings of ILMN. Vanguard Group Inc. lifted its holdings in Illumina by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 18,178,513 shares of the life sciences company’s stock worth $2,531,176,000 after buying an additional 210,755 shares in the last quarter. Edgewood Management LLC increased its position in Illumina by 4.6% in the fourth quarter. Edgewood Management LLC now owns 6,878,495 shares of the life sciences company’s stock worth $957,762,000 after purchasing an additional 302,222 shares during the period. Polen Capital Management LLC raised its holdings in Illumina by 0.6% during the 3rd quarter. Polen Capital Management LLC now owns 5,126,614 shares of the life sciences company’s stock worth $703,782,000 after purchasing an additional 29,153 shares during the last quarter. Loomis Sayles & Co. L P lifted its position in Illumina by 5.5% during the 3rd quarter. Loomis Sayles & Co. L P now owns 4,007,957 shares of the life sciences company’s stock valued at $550,212,000 after purchasing an additional 208,267 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Illumina by 6.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock valued at $500,926,000 after purchasing an additional 225,074 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

About Illumina

(Get Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Further Reading

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.